-
TIPPING POINT QUANTITATIVE BIAS ANALYSIS APPROACHES TO POPULATION-ADJUSTED INDIRECT COMPARISONS WITH INCOMPLETE DATA
Aug 11, 2026, 17:16 PM -
REAL-WORLD FARICIMAB DOSING INTERVALS DIABETIC MACULAR EDEMA: IMPACT ON HEALTHCARE RESOURCE USE, COSTS, AND TRAVEL-RELATED CARBON EMISSIONS
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF ORAL BISPHOSPHONATES FOR OSTEOPENIA IN SINGAPORE: IMPLICATIONS FOR RISK-BASED INTERVENTION THRESHOLDS
Aug 11, 2026, 17:16 PM -
PATIENT-PHYSICIAN DIFFERENCES IN PREFERENCES FOR FINANCIAL INCENTIVES TO IMPROVE MEDICATION ADHERENCE: EVIDENCE FROM A BEST-WORST SCALING STUDY IN CHINA
Aug 11, 2026, 17:16 PM -
ECONOMIC EVALUATIONS OF INTERVENTIONS FOR MULTIPLE LONG-TERM CONDITIONS: A SYSTEMATIC REVIEW OF GLOBAL EVIDENCE
Aug 11, 2026, 17:16 PM -
BEHIND THE COMPARISON: ARE FEASIBILITY ASSESSMENTS ADEQUATELY REPORTED IN PUBLISHED ITCS?
Aug 11, 2026, 17:16 PM -
COST EFFECTIVENESS ANALYSIS OF RECATICIMAB VERSUS TAFOLECIMAB FOR PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA IN CHINA
Aug 11, 2026, 17:16 PM -
COMPARATIVE EVALUATION OF HEMATOLOGICAL PARAMETERS FOR DIAGNOSTIC ACCURACY IN RHEUMATOID ARTHRITIS
Aug 11, 2026, 17:16 PM -
WILL THE NEW NATIONAL HEALTHTECH ACCESS PROGRAMME (NHAP) IMPROVE ACCESS FOR DIGITAL PRODUCTS IN ENGLAND AND WALES? A REVIEW OF DIGITAL PRODUCT SUCCESS TO DATE
Aug 11, 2026, 17:16 PM -
THE MISSING STEM OF THE VALUE FLOWER: HTA IMPLICATIONS WHEN REAL-WORLD VALUE DEPENDS ON SUPPLY-CONSTRAINED HEALTH SYSTEMS
Aug 11, 2026, 17:16 PM -
AN AI-AUGMENTED INTERACTIVE R SHINY TOOL FOR AUTOMATED KAPLAN-MEIER RECONSTRUCTION, PARAMETRIC EXTRAPOLATION, AND HEALTH ECONOMIC EVALUATION
Aug 11, 2026, 17:16 PM -
IMPLICATIONS OF SEX-BASED HETEROGENEITY FOR INTERPRETING REAL-WORLD DISEASE BURDEN IN MYASTHENIA GRAVIS
Aug 11, 2026, 17:16 PM -
A MULTI-COUNTRY EVALUATION OF ACCESS TO BIOLOGICS FOR ATOPIC DERMATITIS IN EUROPE: EVIDENCE FROM THE LEBRIKIZUMAB CASE STUDY
Aug 11, 2026, 17:16 PM -
CURRENT GENAI POLICY IN HTA: THE MISSING MANDATE AND IMPLICATIONS FOR INDUSTRY
Aug 11, 2026, 17:16 PM -
WHY DO SIMILAR CLINICAL DATA RESULT IN DIFFERENT HTA CONCLUSIONS AND REIMBURSEMENT DECISIONS? THE CASE OF SEMAGLUTIDE AND TIRZEPATIDE IN OBESITY
Aug 11, 2026, 17:16 PM -
INCORPORATING THE EFFECTS OF PHARMACEUTICAL WATER POLLUTION INTO A HEALTH TECHNOLOGY ASSESSMENT: AN INTERREG-NWE PREWAPHARM (PREVENTION OF WATER POLLUTION BY PHARMACEUTICALS) PROJECT
Aug 11, 2026, 17:16 PM -
FORECASTING THE FUTURE BURDEN OF CELIAC DISEASE IN HUNGARY: A POPULATION-BASED EPIDEMIOLOGICAL ANALYSIS, 2012-2034
Aug 11, 2026, 17:16 PM -
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC DISEASES: A TARGETED LITERATURE REVIEW OF THE IMPACT OF CHRONIC DISEASES IN SPAIN AND EUROPE
Aug 11, 2026, 17:16 PM -
REVISITING THE DESIGN OF MANAGED ENTRY AGREEMENTS: A METHODOLOGICAL FRAMEWORK TO STREAMLINE THEIR ADOPTION
Aug 11, 2026, 17:16 PM -
VALUE FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT IN BRAZIL'S SUPPLEMENTARY HEALTH SYSTEM: IDENTIFYING THE KEY DRIVERS OF DECISION-MAKING (2021-2025)
Aug 11, 2026, 17:16 PM
